Estudio de utilización de tipo consumo de Imatinib en el tratamiento de Leucemia Mieloide crónica Colombia

Using the database of the SISPRO Social Protection Information System, information was generated on the use and consumption of Imatinib, a drug with a clear tendency towards a monopoly offered as Gleevec® (trademark) and in a generic way for the treatment Of Chronic Myeloid Leukemia, so that by 2013...

Full description

Autores:
García Bermudez, Leidy Catalina
Cruz Velásquez, Heidy Luciana
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2017
Institución:
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
Repositorio:
Repositorio Institucional UDCA
Idioma:
spa
OAI Identifier:
oai:repository.udca.edu.co:11158/707
Acceso en línea:
https://repository.udca.edu.co/handle/11158/707
Palabra clave:
Imatinib Mesilato
Leucemia
Cromosoma filadelfia
Imanitib -- Investigaciones
Leucemia -- Tratamiento con drogas
Rights
closedAccess
License
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
Description
Summary:Using the database of the SISPRO Social Protection Information System, information was generated on the use and consumption of Imatinib, a drug with a clear tendency towards a monopoly offered as Gleevec® (trademark) and in a generic way for the treatment Of Chronic Myeloid Leukemia, so that by 2013 their consumption by sex, age groups and geographical areas was determined, also making the corresponding rate adjustment in which a similar behavior was found between the age group of 55 to the 59 years for both sexes, ages for which it is expected that there is a greater consumption of Imatinib, since according to the natural history of the disease, it is diagnosed at these ages. In addition to the above, a higher consumption in the departments of Bogota D.C., Valle del Cauca and Antioquia is evidenced by the presence of specialized centers with availability of human talent that manages to meet the needs of care in this disease. Due to the problem of the low supply of Imatinib for the high demand of patients with chronic myeloid leukemia, the value paid for mg of this medication was calculated by finding that it is approximately $ 400 in departments such as Chocó and Guajira, while in the Huila is $ 140, comparable results to those issued to SISMED for the year 2013, which can be affirmed that there is a use of Imatinib mostly trademark.